|
Myeloproliferative disease
|
0.010 |
AlteredExpression
|
group |
BEFREE |
AURKA contributes to Janus-kinase-2 (JAK2) activation and increased AURKA protein levels were reported in CD34+ and CD41+ cells of myeloproliferative neoplasm patients, leading to aneuploidy and aberrant megakaryopoiesis.
|
31837568 |
2020 |
|
Arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The present study identified the regulation of Linc00299, via miR-490-3p targeting Aurora kinase A (AURKA), on migration and proliferation of endothelial cells and vascular smooth muscle cells (VSMCs) during atherosclerosis.
|
30734057 |
2019 |
|
Atherosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The present study identified the regulation of Linc00299, via miR-490-3p targeting Aurora kinase A (AURKA), on migration and proliferation of endothelial cells and vascular smooth muscle cells (VSMCs) during atherosclerosis.
|
30734057 |
2019 |
|
Carcinoma, Transitional Cell
|
0.010 |
Biomarker
|
disease |
BEFREE |
Overexpression of aurora kinase A (AURKA) confers a poor prognosis in patients with urothelial carcinoma of the bladder.
|
31597600 |
2019 |
|
Gastrointestinal Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Agents that inhibit AURKA might slow the growth of gastrointestinal tumors with activation of KRAS.
|
30342037 |
2019 |
|
Hepatitis B
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Aurora kinase A promotes hepatitis B virus replication and expression.
|
31376425 |
2019 |
|
Hepatitis C
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, aberrantly methylated AURKA and FOS may be potential therapeutic targets for HCV‑positive HCC.
|
31322223 |
2019 |
|
Refractive Errors
|
0.010 |
Biomarker
|
group |
BEFREE |
The Nidek ARK-1 autorefractor is a useful clinical tool that provides a reasonable and repeatable estimation of refractive error in adults.
|
31107837 |
2019 |
|
Rubella
|
0.010 |
Biomarker
|
disease |
BEFREE |
A new MMR vaccine (JVC-001) was developed, using mumps RIT4385 strain in combination with Japanese measles AIK-C strain and rubella Takahashi strain (MR) vaccine.
|
30724658 |
2019 |
|
Cervical Intraepithelial Neoplasia
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, a total of four DEGs (TYMS, SASH1, CDK1 and AURKA) and two DEmiRNAs (hsa-miR-21 and hsa-miR-99a) may be involved in the pathogenesis of CIN and the progression of CIN into CSCC.
|
31642613 |
2019 |
|
Malignant Squamous Cell Neoplasm
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Although clinical trials of AURA series illustrated that non-small cell lung cancer (NSCLC) with <i>EGFR</i> T790M mutation can benefit from osimertinib, only five LSCC patients were enrolled in total; moreover, the efficacy for LSCC was not shown in the results.
|
31183356 |
2019 |
|
Malignant Pleural Mesothelioma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Gene expression levels of Aurora Kinase A (AURKA), RAD50 as well as DNA damage-binding protein 2 (DDB2) could be identified as prognostic markers in MPM.
|
30700254 |
2019 |
|
Urothelial Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Overexpression of aurora kinase A (AURKA) confers a poor prognosis in patients with urothelial carcinoma of the bladder.
|
31597600 |
2019 |
|
Autoimmune Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Four ES-62 analogues were tested - 11a and 12b, previously shown to be active in mouse models of allergic and autoimmune disease and 16b and AIK-29/62 both of which are structurally related to 11a.
|
29802846 |
2018 |
|
Von Hippel-Lindau Syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The present study showed that von Hippel‑Lindau tumor suppressor (VHL) tumor‑suppressor activity may influence the therapeutic response to Aurora kinase A (AURKA) inhibitors in human renal cell carcinoma (RCC).
|
29845253 |
2018 |
|
Central Nervous System Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
These results provide compelling rationale for clinical testing of alisertib and/or other AURKA inhibitors for potential combination use with TPI 287 against glioblastoma and other CNS neoplasms.
|
29396807 |
2018 |
|
Adult Acute Myeloblastic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Long non-coding RNA taurine-upregulated gene 1 correlates with poor prognosis, induces cell proliferation, and represses cell apoptosis via targeting aurora kinase A in adult acute myeloid leukemia.
|
29654398 |
2018 |
|
Malignant Head and Neck Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Compound 2, the most potent inhibitor of EGFR and AURKA from this series, has been further evaluated in four different squamous cell head and neck cancer cell lines for downstream effects resulting from AURKA and EGFR inhibition.
|
29115879 |
2018 |
|
Hyperactive behavior
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Pathologically, the amplification or activation of AURKA-induced impairment of the LKB1/AMPK signaling pathway contributes to NSCLC initiation and progression, highlighting AURKA as a potential therapeutic target for combatting hyperactive AURKA-driven NSCLCs.
|
28967900 |
2018 |
|
Papillary serous endometrial carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In comparative <i>in vivo</i> experiments, GS-5829 and/or GS-626510 were found more effective than JQ1 at the concentrations/doses used in decreasing tumor growth in both USC-ARK1 and USC-ARK2 mouse xenograft models.<b>Conclusions:</b> GS-5829 and GS-626510 may represent novel, highly effective therapeutics agents against recurrent/chemotherapy-resistant USC-overexpressing c-Myc.
|
29941483 |
2018 |
|
precancerous lesions
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Histopathologic and molecular comparative analyses of intravesical Aurora kinase-A inhibitor Alisertib with bacillus Calmette-Guérin on precancerous lesions of bladder in a rat model.
|
29931492 |
2018 |
|
Head and Neck Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Compound 2, the most potent inhibitor of EGFR and AURKA from this series, has been further evaluated in four different squamous cell head and neck cancer cell lines for downstream effects resulting from AURKA and EGFR inhibition.
|
29115879 |
2018 |
|
Asthma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In addition, we identified a corresponding increase in Aurora Kinase A (AURKA) protein expression in epithelial cells from asthmatics compared to those from non-asthmatics.
|
28137284 |
2017 |
|
Astrocytoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Importantly, interactions between AURKA and AURKB stabilize and protect AURKA/B from degradation, and overexpression of SIX3 does not affect these interactions; SIX3 also acts as a tumor suppressor, and it increases p53 activity and expression at the post-translational level by the negative regulation of AURKA or AURKB, reduces the events of numerical centrosomal aberrations and misaligned chromosomes, and significantly inhibits the proliferation, invasion, and tumorigenesis of astrocytoma in vitro and in vivo.
|
28595628 |
2017 |
|
Lymphatic Metastasis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High expression of phospho-aurora kinase A was associated with lymphatic metastasis such as positive pelvic lymph node and omental involvement (P=0.012 and 0.037).
|
27779297 |
2017 |